Targeting toxins to tumors using microproteins

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$995,124.00
Award Year:
2008
Program:
SBIR
Phase:
Phase II
Contract:
2R44CA128137-02
Agency Tracking Number:
CA128137
Solicitation Year:
2008
Solicitation Topic Code:
n/a
Solicitation Number:
PHS2007-2
Small Business Information
AMUNIX, INC.
AMUNIX, INC., 500 Ellis Street, Suite B, MOUNTAIN VIEW, CA, 94043
Hubzone Owned:
Y
Socially and Economically Disadvantaged:
Y
Woman Owned:
Y
Duns:
621413512
Principal Investigator:
VOLKER SCHELLENBERGER
(408) 540-8129
VSCHELLENBERGER@AMUNIX.COM
Business Contact:
(408) 540-8129
VSchellenberger@amunix.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Treatment of metastatic tumors is a major health challenge. Recently, antibody-based therapies have been developed that are more specific and have fewer side effects compared with conventional chemotherapy. However, the potency of most antibody therapeutics is limited by their inadequate ability to kill tumor cells. Consequently, there is an urgent, unmet need to develop therapeutics that combine the specificity of antibodies for tumor tissues with a potent cytotoxic fun ction. The development of tumor-targeted toxins has yielded promising results and led to one approved product, Ontak (Denileukin). Most molecules however are immunogenic and aggregation prone, have limited stability and require complex manufacturing routes . To achieve clinical and commercial success it is critical for candidates to meet following criteria: 1) high potency; 2) low systemic toxicity; 3) low immunogenicity; 4) high protein stability, lack of aggregation; 5) robust manufacturing. This proposal aims to develop tumor-targeted toxins by combining three elements that confer significant advantages over current approaches: microproteins for tumor binding/internalization; RNAse for cell killing; rPEG to optimize PK properties. In the successful Phase I of this project, we developed tumor-specific microproteins with the following properties: 1) efficient production in E. coli; 2) efficient phage display that enables rapid specificity optimization; 3) effective internalization of toxic payloads; 4) excell ent serum stability. In a separate phase I SBIR project, we developed rPEGs, hydrophilic protein sequences that mimic the properties of chemical polyethylene glycol (PEG) but can be directly fused to other proteins. rPEGs optimize the pharmacokinetics of a product, reduce product immunogenicity, and greatly reduce protein aggregation. Our Phase II goal is to optimize the specificity of our lead microproteins to achieve a gt1000x ration of tumor/normal affinity. Subsequently, we will fuse these optimized mic roproteins to RNAse as toxic payload and rPEG to optimize PK, PD and protein manufacturing. The resulting fusion proteins will be thoroughly evaluated for in vitro and in vivo performance. In addition, we will develop an effective manufacturing process tha t can be transferred with minor modifications to a GMP manufacturer. We aim to generate two lead molecules that will be ready to enter preclinical followed by clinical development. In addition we will generate microprotein-rPEG fusions with defined conjuga tion sites that will be uniquely suitable for the chemical conjugation of toxic payloads. PUBLIC HEALTH RELEVANCE: The development of tumor-targeted toxins have yielded promising results and led to one approved product, Denileukin. However, existing molecules have significant limitations especially immunogenicity and complex manufacturing requirements. This project will use tumor-specific microproteins to address these limitations and develop targeted toxins with the following characteristics: 1) hig h potency; 2) low systemic toxicity; 3) low immunogenicity to allow repeat dosing; 4) good protein stability; 5) lack of aggregation; 6) robust manufacturing process.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government